Navigation Links
IntelliCyt Introduces New System for Multiplexed Screening of Suspension Assays
Date:1/12/2013

Albuquerque, NM, (PRWEB) January 12, 2013

IntelliCyt Corporation, a provider of assay screening solutions for phenotypic drug discovery, antibody discovery and in vitro toxicity testing, today announced the introduction of their new iQue™ Screener. The new system is the latest addition to IntelliCyt’s platform of instrumentation, application-specific reagents, integrated multi-user analysis and informatics tools. The iQue Screener will be unveiled tomorrow at the Society for Laboratory Automation and Screening (SLAS) 2nd Annual Conference in Orlando, Florida.

“The iQue Screener is our next generation system, integrating IntelliCyt’s technology into an instrument that is ideal for the screening environment. Researchers can now evaluate compound effects on non-adherent cell lines, primary immune system cells and molecular interactions using cell or bead-based screening assays”, commented Terry Dunlay, CEO at IntelliCyt. “Laboratories will see a drastic reduction in time to final results and be able to generate higher quality and more reproducible data. Our early access customers have been very happy with the ease of use, workflow support and powerful data analysis capabilities the system provides.”

IntelliCyt’s screening systems for cell and bead-based assays are the first high-throughput, high-content bench top analyzers designed for rapid screening of cells and beads in suspension. Unlike other screening technologies that provide data on a per well basis, IntelliCyt’s technology provides information-rich data on a cell by cell basis in 96- and 384-well microplates. Micro-volume sample delivery combined with rapid sample processing and highly sensitive multiplexing capabilities let researchers in many fields screen large libraries at unprecedented speed and also drastically reduce costs.

About IntelliCyt Corporation

IntelliCyt Corporation develops innovative, high-throughput, high-content cell and bead-based screening solutions for use in phenotypic drug discovery, antibody discovery and in vitro toxicity testing. IntelliCyt’s proprietary technologies, instrumentation, assays and software products address the pervasive need to provide turnkey solutions that increase productivity in pharmaceutical, biotechnology, and life science research. For more information, please visit http://www.intellicyt.com.

Contact:
IntelliCyt Corporation
Michael Sjaastad, Director of Business Development
505-345-9075
MSjaastad(at)intellicyt(dot)com

Read the full story at http://www.prweb.com/releases/2013/1/prweb10314119.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. iLuv Introduces a Range of Accessories to Enhance Apple’s Lightning Devices at 2013 CES
2. RURO Introduces the FreezerPro® ColdTrack RFID Kit
3. Zinman & Company Introduces Year-End Tax Review for Clients Using Virtual Controllership Services
4. White Mountain Process Introduces Squeal-less Mechanical Seal
5. AllCells Introduces Autoimmune Diseased Cells and Tissue Products
6. Vision Research Introduces the Newest Member Of the Phantom®- 1Mpx- v-Series Camera Family
7. JPSA Introduces Picosecond Laser Micromachining System
8. Profit Lifter for Pro Mold Removers: Molderizer Introduces Remediation Product Like No Other
9. WHEATON® Introduces a New Web Community for Scientists, Researchers, and Biopharmaceutical Packagers
10. NextGen introduces its first generation of animal biomarker products for development of brain disorder diagnostics
11. Leading Pharmaceutical Marketing Research and Consulting Company Introduces Intelligent Efficiency Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 2017 http://www.Financialbuzz.com - ... leading causes of death worldwide. There were 8.2 million ... cancer related deaths increased gradually over time, the death ... of various cancers continues to drive demand of biological ... Global Market Insights, Inc. cancer biological therapy market size was ...
(Date:1/19/2017)... Jan. 19, 2017 /PRNewswire -- WuXi AppTec, a ... capability and technology platform, today announced that it ... focused preclinical drug discovery contract research organization (CRO). ... a wholly-owned subsidiary of WuXi, and will continue ... providing greater services. The acquisition will further strengthen ...
(Date:1/19/2017)... Calif. , Jan. 19, 2017  ArmaGen, ... Mathias Schmidt , Ph.D., as chief executive officer, ... of directors. Dr. Schmidt brings to ArmaGen more than ... the research and development of biotherapeutics and pharmaceuticals. ... executive with the diverse experience and skillset necessary ...
(Date:1/19/2017)... ... January 19, 2017 , ... DaVita Clinical Research ... drug and device development, and Prism Clinical Research , a leader in ... Verified Clinical Trials (VCT) has been selected by both companies as ...
Breaking Biology Technology:
(Date:1/12/2017)... 12, 2017  Trovagene, Inc. (NASDAQ: TROV ... today announced that it has signed agreements with seven ... the Middle East for commercialization ... the first wave of international distribution agreements for Trovagene,s ... samples. The initial partners will introduce Trovagene,s ...
(Date:1/6/2017)... Jan. 6, 2017  Privately-held CalciMedica, Inc., announced ... healthy volunteers of a novel calcium release-activated calcium ... pancreatitis. Acute pancreatitis, sudden painful ... disorder, but can be very serious.  In severe cases ... where extended hospital stays, time in the ICU ...
(Date:1/3/2017)... , Jan. 3, 2017 Onitor, provider of ... of Onitor Track, an innovative biometric data-driven program designed ... this month at the 2017 Consumer Electronics Show (CES) ... In the U.S., the World Health Organization (WHO), ... two-thirds of adults who are overweight or obese. WHO ...
Breaking Biology News(10 mins):